Ever Supreme Bio Technology , Ltd Profit Margin

Ever Supreme Bio Technology , Ltd (6712.TWO) currently reports a profit margin of 40.74% as of September 2026. That compares with 51.78% in the prior-year period — down 21.3% year over year. That is above the Healthcare sector average of 17.63%. Use the charts on this page to explore Ever Supreme Bio Technology , Ltd's profit margin history and peer comparisons.

Ever Supreme Bio Technology , Ltd's profit margin decreased from 51.78% to 40.74% — a 21.3% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ever Supreme Bio Technology , Ltd's profit margin of 40.74% is higher than the Healthcare sector average of 17.63%. That is roughly 131.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Ever Supreme Bio Technology , Ltd's current 40.74% should be judged against Healthcare norms (sector average: 17.63%) and against 6712.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 40.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Ever Supreme Bio Technology , Ltd, and consider following 6712.TWO for alerts when major investors trade the stock.